Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Apatorsen · OGX-427

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: heat shock protein 27 (HSPB1) · developed by Achieve Life Sciences

Phase 2 Most advanced trial (none active)

ACHV Developer

3 Registered trials

What is Apatorsen?

Apatorsen (OGX-427) is a second-generation antisense oligonucleotide designed to bind Hsp27 mRNA and suppress tumor cell expression of heat shock protein 27, a chaperone over-expressed in various cancers. It is being studied in urothelial (bladder) carcinoma and squamous cell lung cancer, including in combination with cytotoxic chemotherapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: OGX-427
Drug type: Oligonucleotide (Antisense oligonucleotide)
Targets: heat shock protein 27 (HSPB1)
Mechanism: Gene silencing: heat shock protein 27 (HSPB1)
Pathways: apoptosis, cytoprotection under cellular stress
Therapy area: Oncology
Developer: Achieve Life Sciences (ACHV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: IFJ6X26JW6

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02423590	Phase 2	Squamous Cell Lung Cancer	Unknown	ACHV
NCT01780545	Phase 2	Bladder Cancer	Completed	ACHV
NCT01454089	Phase 2	Urologic Neoplasms	Completed	ACHV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder CancerMetastatic Bladder CancerSquamous Cell Lung CancerUrinary Tract NeoplasmsUrologic NeoplasmsUrothelial Carcinoma

More from Achieve Life Sciences

Custirsen Phase 3 Cytisinicline Phase 3 Paclitaxel Vitamin E-Based Phase 2 Tenifatecan Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ACHV page.

Follow ACHV, the company behind Apatorsen

See ACHV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACHV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z